Cedars-Sinai Cancer Center: Adolescents and Young Adults Cancer Conference

The conference provides a chance to educate and update community-based clinicians on best practices for multi-disciplinary management of adolescents and young adult cancer across the Cedars-Sinai Cancer network. The sessions will address the role of surgery, advances in radiation oncology, and current best systemic therapies along with highly debated treatments in sarcoma, medical imaging and pathological advancements. In particular molecular pathology will also be highlighted together with presenters for immuno-oncology, survivorship, medical genetics, and pharmacy.

1. Apply evidence based medicine to improve diagnosis, treatment, and overall management of patients with malignant sarcomas.
2. Assess current and evolving practices in the treatment of AYA to help define outcomes and treatment options for patients.
3. Use AJCC or other appropriate staging in clinical practice, including appropriate prognostic indicators and evidence based national guidelines for treatment planning.
4. Incorporate an interprofessional approach to improve the care of patients with malignant sarcomas.

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Robert A. Figlin, MD
Cedars-Sinai

Course Director, Faculty

Nothing to disclose

Jane C. Figueiredo , PhD
Cedars-Sinai Medical Center

Course Director, Faculty

Nothing to disclose

James Hu, MD
Cedars Sinai

Course Director, Faculty

Other: Advisory Board and Speaker Fees-Springworks Therapeutics

Leo Mascarenhas, MD
Cedars-Sinai Medical Center

Course Director, Faculty

Advisor-AMGEN (Relationship has ended)|PrincipalNamedInvestigator-AstraZeneca (Relationship has ended)|PrincipalNamedInvestigator-Jazz Pharmaceuticals (Relationship has ended)|Advisor-Gilead (Relationship has ended)|PrincipalNamedInvestigator-Eli Lilly and Company (Relationship has ended)|PrincipalNamedInvestigator-Bayer Corporation (Relationship has ended)|PrincipalNamedInvestigator-Incyte Corporation (Relationship has ended)|PrincipalNamedInvestigator-Takeda Pharmaceuticals, Inc. (Relationship has ended)|PrincipalNamedInvestigator-E.R. Squibb & Sons (Relationship has ended)

Philicia Moonsamy, MD
Cedars-Sinai

Course Director, Faculty

Nothing to disclose

Earl Brien, MD
CSMC

Faculty

Consultant-United Orthopedics

Jessica L. Chan, MD
Cedars-Sinai Medical Center

Faculty

Advisor-BINTO

Fahima Dossa, MD, PhD
Memorial Sloan Kettering Cancer Center
Canada

Faculty

Nothing to disclose

Matthew Gayhart, MD

Faculty

Nothing to disclose

Matthew T Juarez, MD
Hematology/Oncology

Faculty

Nothing to disclose

Mitchell Kamrava, MD
Cedars Sinai

Faculty

Advisor-Alessa (Relationship has ended)|Royalties or Patent Beneficiary-Springer book rotyalties|Other: DSMB-GT Medical|Other: DSMB-Alessa

Inderjit Mehmi, MD
Cedars-Sinai

Faculty

Nothing to disclose

Michael Roth, MD
MD Anderson Cancer Center

Faculty

PrincipalNamedInvestigator-Pfizer, Inc.

David Shia, MD, PhD
CSMC

Faculty

Nothing to disclose

Zul Surani, MPH
Cedars-Sinai Cancer Center

Faculty

Nothing to disclose

Saturday, October 11, 2025